-
Nihon Igaku Hoshasen Gakkai Zasshi.... Nov 1986
Topics: Animals; Biological Products; Bone Marrow; Lethal Dose 50; Male; Mice; Picibanil; Radiation Dosage; Radiation-Protective Agents; Spleen; Whole-Body Irradiation
PubMed: 3547316
DOI: No ID Found -
Immunopharmacology and Immunotoxicology 1989The inactivate streptococcal preparation OK432 activates the cytotoxic function of natural killer (NK) cells. Moreover, it induces cytotoxic activity against freshly...
The inactivate streptococcal preparation OK432 activates the cytotoxic function of natural killer (NK) cells. Moreover, it induces cytotoxic activity against freshly isolated tumor cells. The present study was aimed at assessing whether OK432-activated effector cells expressed cytotoxicity against tumor cells pleiotropically resistant to cancer chemotherapy agents. OK432-treated lymphoid cells killed the multidrug resistant (MDR) LOVO DX line as efficiently as drug sensitive parental LOVO N carcinoma line. Effector cells involved in killing MDR cells were low density large granular lymphocytes with NK functions. Activation of effector cells has the potential to complement conventional cytoreductive therapy by eliminating residual-tumor cells surviving and resistant to chemotherapy.
Topics: Biological Products; Colonic Neoplasms; Doxorubicin; Drug Resistance; Humans; Lymphocyte Activation; Lymphocytes; Picibanil; T-Lymphocytes, Cytotoxic; Tumor Cells, Cultured
PubMed: 2621319
DOI: 10.3109/08923978909005369 -
International Immunopharmacology Mar 2024Radiofrequency ablation (RFA) has been used as an alternative to surgical management of early-stage hepatocellular carcinoma (HCC). However, when large and irregular...
Radiofrequency ablation (RFA) has been used as an alternative to surgical management of early-stage hepatocellular carcinoma (HCC). However, when large and irregular HCCs are subjected to RFA, a safety margin is usually difficult to obtain, thus causing a sublethal radiofrequency hyperthermia (RFH) at the ablated tumor margin. This study investigated the feasibility of using RFH to enhance the effect of OK-432 on HCC, with the aim to generate a tumor-free margin during RFA of HCC. Our results showed OK-432 could activate the cGAS-STING pathway, and RFH could further enhance the activation. Meanwhile, RFH could induce a high expression of TLR4, and TLR4 might be an upstream molecular of the cGAS-STING pathway. The combined therapy of RFH with OK-432 resulted in a better tumor response, and a prolonged survival compared to the other three treatments. In conclusion, RFH in combination with OK-432 might reduce the residual and recurrent tumor after RFA of large and irregular HCCs, and serve as a new option for other solid malignancies treated by RFA.
Topics: Carcinoma, Hepatocellular; Hyperthermia, Induced; Liver Neoplasms; Neoplasm Recurrence, Local; Picibanil; Retrospective Studies; Toll-Like Receptor 4; Antineoplastic Agents; Animals; Mice; Cell Line, Tumor; Radiofrequency Ablation; Mice, Inbred C57BL; Nucleotidyltransferases; Membrane Proteins; Male
PubMed: 38442584
DOI: 10.1016/j.intimp.2024.111769 -
Nihon Gan Chiryo Gakkai Shi Dec 1987
Topics: Administration, Oral; Aged; Aged, 80 and over; Biological Products; Combined Modality Therapy; Female; Humans; Immunization, Passive; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Picibanil; Pilot Projects
PubMed: 3449590
DOI: No ID Found -
Journal of Pediatric Surgery Sep 2010OK-432 therapy is effective for the treatment of macrocystic lymphatic malformations (LMs), but the optimal management of patients with microcystic LMs associated with...
OK-432 therapy is effective for the treatment of macrocystic lymphatic malformations (LMs), but the optimal management of patients with microcystic LMs associated with large chylous pleural effusions or chylous ascites is not resolved. We performed thoracoscopic- or laparoscopic-guided injection of OK-432 for 2 patients with diffuse microcystic LMs accompanied by refractory chylous pleural effusion or chylous ascites. Both cases responded well to OK-432 therapy with improvement/resolution of fluid collections and associated symptoms. We recommend the use of OK-432 therapy as a promising treatment for microcystic LMs with functionally significant lymphatic fluid collections.
Topics: Adult; Chylothorax; Chylous Ascites; Female; Humans; Infant, Newborn; Injections; Lymphatic Abnormalities; Picibanil; Pleural Effusion; Sclerosing Solutions
PubMed: 20850615
DOI: 10.1016/j.jpedsurg.2010.06.010 -
Journal of Pediatric Surgery Mar 1991To avoid surgery-related complications, intralesional OK-432 therapy was used in 23 patients with unresectable lymphangiomas (1986 through 1989). Total or near total...
To avoid surgery-related complications, intralesional OK-432 therapy was used in 23 patients with unresectable lymphangiomas (1986 through 1989). Total or near total shrinkage of the lesions, without serious complication, was noted in 10, marked shrinkage in 8, slight shrinkage in 3, and no response was noted in the remaining 2. Recurrence of the lesions has not been observed during follow-up (4 to 35 months). The side effects of OK-432 therapy were a fever for 2 to 3 days and a local inflammatory reaction lasting 3 to 5 days. The local inflammation did not cause any damage to the overlying skin and did not lead to scar formation. The results suggest that intralesional OK-432 therapy is effective for most unresectable lymphangiomas.
Topics: Adolescent; Child; Child, Preschool; Female; Head and Neck Neoplasms; Humans; Infant; Infant, Newborn; Injections, Intralesional; Lymphangioma; Male; Picibanil; Tomography, X-Ray Computed
PubMed: 2030471
DOI: 10.1016/0022-3468(91)90500-s -
Pediatric Surgery International May 2016We have recently shown that the relative TLR4 expression on monocytes of low responding pediatric patients after OK-432 treatment is significantly reduced after...
PURPOSE
We have recently shown that the relative TLR4 expression on monocytes of low responding pediatric patients after OK-432 treatment is significantly reduced after stimulation with lipopolysaccharide (LPS) compared with high responding children. The aim of this study was to perform further analysis to explain this observation.
METHODS
Monocytes from children with high (HR, n = 5) and low response (LR, n = 6) after previous OK-432 treatment were stimulated with LPS for 20 h and analyzed with fluorescence-activated cell sorting (mean fluorescence intensity, MFI; level of significance P ≤ 0.05).
RESULTS
Mean MFI after LPS stimulation was comparable in both groups (HR 1142 ± 652 units, LR 839 ± 427 units, P = 0.85). Significant changes after LPS stimulation are explained by higher pre-stimulation values in the LR group compared with the HR group (950 ± 718 vs. 477 ± 341, P = 0.25) with considerable differences of the mean expression changes after LPS stimulation (HR 665 ± 683 vs. LR -111 ± 605, P = 0.08).
CONCLUSION
The previously shown reduced TLR4 upregulation on monocytes after LPS stimulation in the LR group compared with the HR group can be primarily explained by TLR preconditioning. This observation implies the use of absolute values with definite thresholds.
Topics: Child; Child, Preschool; Female; Humans; Infant; Lipopolysaccharides; Lymphatic Abnormalities; Male; Monocytes; Picibanil; Sclerosing Solutions; Toll-Like Receptor 4
PubMed: 26801484
DOI: 10.1007/s00383-016-3865-6 -
The Laryngoscope Jan 2012
Topics: Adult; Aged; Humans; Middle Aged; Picibanil; Thyroglossal Cyst; Young Adult
PubMed: 21994012
DOI: 10.1002/lary.22363 -
European Journal of Pediatric Surgery :... Apr 2003Cystic hygroma or lymphangioma (LA) is a disfiguring benign lesion commonly seen in the neck and face regions in children. Extensive neck/face resectional surgery is...
BACKGROUND/PURPOSE
Cystic hygroma or lymphangioma (LA) is a disfiguring benign lesion commonly seen in the neck and face regions in children. Extensive neck/face resectional surgery is frequently performed for this condition, often with disappointing results. An attractive alternative to surgery is injection, sclerosing therapy. OK-432 injection therapy has been characterised as a novel treatment of LA since 1987. Since this first report, there have been a number of articles from different institutions reporting variable success rates with its use. This has resulted in uncertainty and confusion among physicians, surgeons and parents alike as to in whom, when, and how to treat patients with this modality.
METHOD
A prospective study over a five-year period. Thirty-five patients were injected with this agent, 1 to 4 times, depending on response.
RESULT
In patients with macrocystic LA, complete regression was achieved in 96 %. Patients with microcystic LA responded poorly or not at all.
CONCLUSION
The anatomical appearance of the malformation on computerised tomography (or sonar) scan is crucial in determining the treatment strategy taken; macrocystic lesions respond almost universally to OK-432 injections, whereas patients with microcystic disease generally do not respond and should therefore not be injected with this agent.
Topics: Antineoplastic Agents; Child; Child, Preschool; Female; Head and Neck Neoplasms; Humans; Infant; Infant, Newborn; Lymphangioma; Male; Picibanil
PubMed: 12776241
DOI: 10.1055/s-2003-39581 -
Yonsei Medical Journal Apr 2007The aim of this study was to demonstrate OK- 432 sclerotherapy efficacy for treatment of simple renal cysts.
PURPOSE
The aim of this study was to demonstrate OK- 432 sclerotherapy efficacy for treatment of simple renal cysts.
MATERIALS AND METHODS
Twenty patients with 25 symptomatic or large simple cysts were treated by ultrasonography (US)-guided percutaneous aspiration and injection of OK-432 (8 men and 12 women, mean age 63.6 years, SD 9.5). Six patients presented with flank pain, 14 presented with renal mass; renal cyst location was right, left, or bilateral sided in 9, 8, and 8 kidneys, respectively. Patients were evaluated by clinical assessment, US, or CT scan 3 months following the procedure. Complete and partial success was defined as symptom resolution with either total cyst ablation or greater than 70% reduction, respectively. Failure was defined as 30% of cyst size recurrence and/or persistent symptoms.
RESULTS
Average reduction was 93.0%. Complete and partial resolution occurred in 11 (44.0%) and 13 (52.0%) cysts, respectively. One case was defined as failure, with a 64.2% size reduction from 10.9cm to 3.9cm (volume reduction rate 95.4%). Renal pain improved in all patients, regardless of complete or partial resolution. Minor complications occurred in 3 patients, 2 developed leukocytosis and 1 had mild fever (< 38.5 degrees C) following aspiration and sclerotherapy. Successful treatment was achieved with conservative measures and NSAID therapy.
CONCLUSION
Percutaneous treatment of simple renal cysts with OK-432 sclerotherapy was found to be a safe, effective and minimally invasive procedure.
Topics: Adult; Aged; Female; Functional Laterality; Humans; Kidney Diseases, Cystic; Male; Middle Aged; Picibanil; Sclerotherapy; Treatment Outcome
PubMed: 17461526
DOI: 10.3349/ymj.2007.48.2.270